Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) —  Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that it has launched an upgraded version of its clonoSEQ assay for measurable residual disease (MRD) detection in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA). The enhanced clonoSEQ assay, which incorporates an optimized DNA extraction methodology and maximizes sample input, delivers a 7-fold increase in sensitivity. The assay leverages...

NASHUA, N.H., March 11, 2025 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, 2024, after market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, March 19, 2025. Earnings call details are as follows: Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 174549Webcast: https://www.webcaster4.com/Webcast/Page/2879/52064 About iCAD, Inc. iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua,...

Funded by a grant from the Roblox Community Fund, AVID’s Creator Planet integrates with key educational standards and includes free classroom resources for teachers and students SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) — Today, AVID (Advancement Via Individual Determination), a leader in closing the opportunity gap for students, and Super League (Nasdaq: SLE), a leader in redefining the gaming industry as a media channel, announce the launch of AVID Creator Planet, an educational adventure on Roblox designed for students ages 13+ to learn valuable executive function and durable skills in and out of the classroom. Funded by a grant from the Roblox Community Fund, AVID Creator Planet focuses on practicing durable skills such as problem-solving, critical thinking, collaboration, and communication. Each phase – from planning and...

Strategic name change reflects company’s evolution and global market presence ORLANDO, Fla., March 11, 2025 (GLOBE NEWSWIRE) — Abacus Life (NASDAQ: ABL), a leader in the alternative asset management space, today announced it has rebranded to Abacus Global Management (abacusgm.com), effective immediately. The new name better reflects the company’s expanded global presence and comprehensive suite of financial services spanning life solutions, asset management, wealth management, and technology solutions. The company’s focus on innovative technology represents a core and growing part of its business strategy going forward. “Our evolution to Abacus Global Management represents a significant milestone in our company’s journey, to revolutionize financial services though expert asset management leveraging advanced technology and to deliver...

The Assigned FDA Approval Goal Date is June 4, 2025 TORONTO, March 11, 2025 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company hyper-focused on the commercialization of Ketamine, is pleased to announce today that the Company has received an Amendment Acknowledgement Letter (“AAL”) from the U.S. Food and Drug Administration (“FDA”) for its New Drug Application for Ketamine. In the AAL, the FDA determined this is a minor amendment, meets the criteria for priority review, and assigned an approval goal date of June 4, 2025. Fabio Chianelli, Chairman and CEO of PharmaTher, commented: “I am very pleased with the new FDA approval goal date of June 4, 2025 for our Ketamine drug. We are focused on solving the shortage issue of Ketamine and becoming...

MINNEAPOLIS, March 11, 2025 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights:CMS four-fold payment increase to $1,639 for Aquadex Ultrafiltration Therapy in the outpatient setting effective January 1, 2025. New data published in JACC: Heart Failure showed Aquadex ultrafiltration reduced heart failure events by 60% compared to IV diuretics. Full year operating cost reduction of $5.9 million, or 26%, compared to the prior year. Revenue of $2.3 million, a 9% decrease compared to the prior year quarter. Consumables utilization growth of 21% compared to the prior year quarter. Critical Care customer category revenue...

Measured Hiring Strategy to Support Operational Excellence and Service Capabilities WALNUT, CA, March 11, 2025 (GLOBE NEWSWIRE) — Armlogi Holding Corp. (“Armlogi” or the “Company”) (Nasdaq: BTOC), a U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions related to warehouse management and order fulfillment, today announced workforce expansion, with employee headcount increasing by 20% over the past 20 months. Armlogi has adopted a disciplined approach to scaling its operations, as it endeavors to maintain service quality.  Since July 2023, Armlogi grew from 173 employees to 208 employees as of March 2025. This measured expansion aligns with increasing client demand and the Company’s enhanced service offerings. “We believe that our workforce development strategy...

Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported fourth quarter and full year 2024 financial results and provided an operational update. Fourth Quarter 2024 Financial and Operational HighlightsAchieved...

SHANGHAI, March 11, 2025 (GLOBE NEWSWIRE) — Atour Lifestyle Holdings Limited (“Atour” or the “Company”) (NASDAQ: ATAT), a leading hospitality and lifestyle company in China, today announced that it will report its unaudited financial results for the fourth quarter and full year of 2024 on Tuesday, March 25, 2025, before the U.S. markets open. The Company will host a conference call at 7:00 AM U.S. Eastern time on Tuesday, March 25, 2025 (or 7:00 PM Beijing/Hong Kong time on the same day). A live webcast of the conference call will be available on the Company’s investor relations website at https://ir.yaduo.com, and a replay of the webcast will be available following the session. For participants who wish to join the conference call via telephone, please pre-register using the link provided below. Upon registering, each participant...

HONG KONG, March 11, 2025 (GLOBE NEWSWIRE) — Powell Max Limited (Nasdaq: PMAX) (the “Company” or “Powell Max”), a financial communications services provider headquartered in Hong Kong, announced that it has received a notification letter (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing of the Company’s Class A Ordinary Shares (the “Ordinary Shares”) on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rules (the “Minimum Bid Price Requirement”) because the closing bid price for the Ordinary Shares had been below $1.00 for 30 consecutive business days. The Notice indicated that the Company has 180 days, or until September 1, 2025 (the “Compliance Deadline”), to regain compliance with the Minimum Bid Price...